In vivo CYP3A activity in palliative care patients: study protocol for a single arm prospective trial

Background: Drug interactions are a common cause for escalation of debilitating symptoms in palliative care patients. CYP3A is the most relevant CYP enzyme in humans involved in metabolism of about half of all available pharmaceuticals.Objective: To increase knowledge about the CYP3A enzyme and the...

Full description

Saved in:
Bibliographic Details
Main Authors: Geist, Marcus Julian Peter (Author) , Bardenheuer, Hubert J. (Author) , Burhenne, Jürgen (Author) , Mikus, Gerd (Author)
Format: Article (Journal)
Language:English
Published: 1 May 2018
In: Journal of palliative medicine
Year: 2018, Volume: 21, Issue: 5, Pages: 686-688
ISSN:1557-7740
DOI:10.1089/jpm.2017.0461
Online Access:Verlag, Volltext: https://doi.org/10.1089/jpm.2017.0461
Verlag: https://www.liebertpub.com/doi/10.1089/jpm.2017.0461
Get full text
Author Notes:Marcus J.P. Geist, Hubert J. Bardenheuer, Jürgen Burhenne, and Gerd Mikus

MARC

LEADER 00000caa a22000002c 4500
001 1685137210
003 DE-627
005 20230427200437.0
007 cr uuu---uuuuu
008 191211s2018 xx |||||o 00| ||eng c
024 7 |a 10.1089/jpm.2017.0461  |2 doi 
035 |a (DE-627)1685137210 
035 |a (DE-599)KXP1685137210 
035 |a (OCoLC)1341281369 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Geist, Marcus Julian Peter  |d 1981-  |e VerfasserIn  |0 (DE-588)136086713  |0 (DE-627)57715009X  |0 (DE-576)300822995  |4 aut 
245 1 0 |a In vivo CYP3A activity in palliative care patients  |b study protocol for a single arm prospective trial  |c Marcus J.P. Geist, Hubert J. Bardenheuer, Jürgen Burhenne, and Gerd Mikus 
264 1 |c 1 May 2018 
300 |a 3 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 11.12.2019 
520 |a Background: Drug interactions are a common cause for escalation of debilitating symptoms in palliative care patients. CYP3A is the most relevant CYP enzyme in humans involved in metabolism of about half of all available pharmaceuticals.Objective: To increase knowledge about the CYP3A enzyme and the impact of drug interactions on its activity to improve dosing in palliative care patients.Design: The prospective clinical trial uses a secure method of analyzing CYP3A activity in humans: Administration of a marker substance followed by the determination of its blood concentrations as well as the concentrations of its metabolite at certain points of time and corresponding metabolic clearance calculations.Setting: The ongoing trial is carried out at a palliative care unit under real-life clinical conditions.Measurements: A four-hour pharmacokinetic profile after oral administration of the marker substance (microdose of midazolam) will be obtained from each enrolled patient. Plasma concentrations of midazolam and its primary metabolite will be quantified by mass spectrometry techniques. CYP3A activity will be calculated as partial metabolic clearance from a limited sampling area under the curve. All other drugs taken by the participating patients will be considered as well as recent blood test results and the patients' diagnoses.Conclusions: This is the first prospective study dealing with drug metabolism in patients on a palliative care unit. The trial is based on reliable and established methods aiming to provide improved dosing regimens and thus optimize pharmacological therapies in this specialty. 
700 1 |a Bardenheuer, Hubert J.  |e VerfasserIn  |0 (DE-588)1064859208  |0 (DE-627)815238819  |0 (DE-576)424204681  |4 aut 
700 1 |a Burhenne, Jürgen  |d 1963-  |e VerfasserIn  |0 (DE-588)1034228889  |0 (DE-627)745126987  |0 (DE-576)381858197  |4 aut 
700 1 |a Mikus, Gerd  |e VerfasserIn  |0 (DE-588)110903137  |0 (DE-627)691097941  |0 (DE-576)336988710  |4 aut 
773 0 8 |i Enthalten in  |t Journal of palliative medicine  |d Larchmont, NY : Liebert, 1998  |g 21(2018), 5, Seite 686-688  |h Online-Ressource  |w (DE-627)324823282  |w (DE-600)2030890-5  |w (DE-576)273879960  |x 1557-7740  |7 nnas  |a In vivo CYP3A activity in palliative care patients study protocol for a single arm prospective trial 
773 1 8 |g volume:21  |g year:2018  |g number:5  |g pages:686-688  |g extent:3  |a In vivo CYP3A activity in palliative care patients study protocol for a single arm prospective trial 
856 4 0 |u https://doi.org/10.1089/jpm.2017.0461  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.liebertpub.com/doi/10.1089/jpm.2017.0461  |x Verlag 
951 |a AR 
992 |a 20191211 
993 |a Article 
994 |a 2018 
998 |g 110903137  |a Mikus, Gerd  |m 110903137:Mikus, Gerd  |d 910000  |d 910100  |e 910000PM110903137  |e 910100PM110903137  |k 0/910000/  |k 1/910000/910100/  |p 4  |y j 
998 |g 1034228889  |a Burhenne, Jürgen  |m 1034228889:Burhenne, Jürgen  |d 910000  |d 910100  |e 910000PB1034228889  |e 910100PB1034228889  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1064859208  |a Bardenheuer, Hubert J.  |m 1064859208:Bardenheuer, Hubert J.  |d 910000  |d 910300  |e 910000PB1064859208  |e 910300PB1064859208  |k 0/910000/  |k 1/910000/910300/  |p 2 
998 |g 136086713  |a Geist, Marcus Julian Peter  |m 136086713:Geist, Marcus Julian Peter  |d 910000  |d 910300  |e 910000PG136086713  |e 910300PG136086713  |k 0/910000/  |k 1/910000/910300/  |p 1  |x j 
999 |a KXP-PPN1685137210  |e 3563631042 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Marcus Julian Peter","family":"Geist","role":"aut","display":"Geist, Marcus Julian Peter","roleDisplay":"VerfasserIn"},{"family":"Bardenheuer","given":"Hubert J.","roleDisplay":"VerfasserIn","display":"Bardenheuer, Hubert J.","role":"aut"},{"given":"Jürgen","family":"Burhenne","role":"aut","roleDisplay":"VerfasserIn","display":"Burhenne, Jürgen"},{"display":"Mikus, Gerd","roleDisplay":"VerfasserIn","role":"aut","family":"Mikus","given":"Gerd"}],"title":[{"title":"In vivo CYP3A activity in palliative care patients","subtitle":"study protocol for a single arm prospective trial","title_sort":"In vivo CYP3A activity in palliative care patients"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 11.12.2019"],"language":["eng"],"recId":"1685137210","name":{"displayForm":["Marcus J.P. Geist, Hubert J. Bardenheuer, Jürgen Burhenne, and Gerd Mikus"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"1 May 2018"}],"id":{"eki":["1685137210"],"doi":["10.1089/jpm.2017.0461"]},"physDesc":[{"extent":"3 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Larchmont, NY","dateIssuedDisp":"1998-","publisher":"Liebert","dateIssuedKey":"1998"}],"id":{"eki":["324823282"],"zdb":["2030890-5"],"issn":["1557-7740"]},"pubHistory":["1.1998 -"],"part":{"issue":"5","pages":"686-688","year":"2018","extent":"3","volume":"21","text":"21(2018), 5, Seite 686-688"},"note":["Gesehen am 13.01.06"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"In vivo CYP3A activity in palliative care patients study protocol for a single arm prospective trialJournal of palliative medicine","language":["eng"],"recId":"324823282","title":[{"title":"Journal of palliative medicine","title_sort":"Journal of palliative medicine"}]}]} 
SRT |a GEISTMARCUINVIVOCYP31201